GH Research (GHRS) Other Non-Current Assets (2025)
GH Research's (GHRS) quarterly Other Non-Current Assets came in at $1.6 million in Q4 2025, up 40.62% quarter-over-quarter from $1.2 million in Q3 2025.
GH Research (GHRS) Other Non-Current Assets (2025) Analysis & Trends
GH Research's Other Non-Current Assets history runs 1 years deep, the most recent figure standing at $1.6 million for Q4 2025.
- On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $1.6 million in Q4 2025; TTM through Dec 2025 was $1.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.6 million, changed N/A from the prior year.
- Other Non-Current Assets grew to $1.6 million in Q4 2025 per GHRS's latest filing, from $1.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.7 million in Q2 2025 and bottomed at $1.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | GH Research | 1.69 Bn | 1.69 Bn | - | 1.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 1.66 Mn |
| Mar 31, 2025 | 1.09 Mn |